CIM
IDXX icon

Contravisory Investment Management’s Idexx Laboratories IDXX Stock Holding History

Contravisory Investment Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-101
Closed -$56.8K – 417
2026
Q1 		$56.8K Sell
101
-8
-7% -$5.13K 0.01% 264
2025
Q4 		$73.7K Buy
+109
New +$74.2K 0.01% 266
2017
Q4 		– Sell
-23
Closed -$4K – 477
2017
Q3 		$4K Buy
+23
New +$3.64K ﹤0.01% 305

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Contravisory Investment Management's IDXX Position: Q2 2026 in Review

Contravisory Investment Management sold out of Idexx Laboratories (IDXX) in Q2 2026, closing a stake of 101 shares — an estimated $56.8K sold.

Contravisory Investment Management first reported a position in IDXX in Q3 2017 and held it in 3 quarters. The position peaked at $73.7K in Q4 2025. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Contravisory Investment Management reported no remaining Idexx Laboratories position as of Q2 2026 after selling out during the quarter.
  • Contravisory Investment Management sold 101 Idexx Laboratories shares in Q2 2026, an estimated $56.8K.
  • Contravisory Investment Management first reported a position in Idexx Laboratories in Q3 2017 and held it in 3 quarters.
  • Contravisory Investment Management's Idexx Laboratories position peaked at $73.7K in Q4 2025.
  • 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.